Core Viewpoint - Enphase Energy, Inc. is facing a class action lawsuit for allegedly making false statements and failing to disclose critical information regarding its financial and operational prospects during the specified class period [3][4]. Group 1: Class Action Details - The class action lawsuit is titled Tripathi v. Enphase Energy, Inc., and it includes purchasers or acquirers of Enphase Energy securities from April 22, 2025, to October 28, 2025 [1]. - Investors have until April 20, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Enphase Energy overstated its ability to manage channel inventory and mitigate the effects of the termination of the Residential Clean Energy Credit [3]. Group 2: Financial Impact - On October 28, 2025, Enphase Energy reported third-quarter financial results, indicating that elevated channel inventory would lead to lower battery storage shipments in the fourth quarter of 2025 [4]. - The expiration of the 25D Credit is expected to negatively impact revenues for the first quarter of 2026 [4]. - Following the announcement, Enphase Energy's stock price fell by more than 15% [4]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Enphase Energy securities during the class period to seek appointment as lead plaintiff [5]. - A lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [5]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 [6]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years [6].

Core Viewpoint - A class action lawsuit has been filed against Plug Power Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of New York, captioned Ortolani v. Plug Power Inc., et al., No. 1:26-cv-00165 [3]. - Investors have until April 3, 2026, to request to be appointed to lead the case, with claims asserted under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Company Background - Plug Power specializes in hydrogen fuel cell turnkey solutions for electric mobility and stationary power markets, and develops infrastructure such as hydrogen production plants [4]. - The company announced a "closed a $1.66 billion loan guarantee" from the U.S. Department of Energy to finance the construction of hydrogen production facilities [4]. Group 3: Stock Performance and Events - On October 7, 2025, Plug Power's stock dropped by $0.26 per share (6.3%) following the abrupt departure of its CEO and President [5]. - On November 10, 2025, the company announced the suspension of activities under the DOE loan program, leading to a further stock drop of $0.09 per share (3.4%) [6]. - A report on November 13, 2025, confirmed the suspension of plans to construct hydrogen facilities, resulting in a stock decline of $0.48 per share (17.6%) [7].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is filed by Bleichmar Fonti & Auld LLP on behalf of investors in Ardent Health securities, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Middle District of Tennessee [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections" while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health disclosed a $43 million revenue decrease for the quarter and increased its professional liability reserves by $54 million, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. and its executives due to significant stock price drops attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled Lupia v. Fermi Inc., et al., No. 1:26-cv-00050 [3]. - Investors have until March 6, 2026, to request to lead the case, with claims of securities fraud under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Sections 11 and 15 of the Securities Act of 1933 [3]. Group 2: Company Background - Fermi Inc. is an energy and AI infrastructure company aiming to build large-scale nuclear reactors to support grid-independent data centers for AI companies [4]. - The company's flagship project, Project Matador, is designed to provide dedicated power for AI workloads [4]. Group 3: IPO and Allegations - Fermi completed its IPO in October 2025, claiming strong demand for Project Matador and securing a 20-year lease with an investment-grade-rated tenant [5]. - Allegations suggest that Fermi overstated tenant demand and misrepresented the agreement with the First Tenant [6]. Group 4: Stock Price Impact - On December 12, 2025, Fermi's stock dropped by $5.16 per share, over 33%, following the termination of the Advance in Aid of Construction Agreement by the First Tenant [7].

Core Viewpoint - The Navan class action lawsuit alleges that Navan, Inc. and its executives misled investors regarding the company's financial health and future expenses during its IPO, leading to significant stock price declines after the IPO [1][3][4]. Group 1: Class Action Lawsuit Details - The lawsuit seeks to represent purchasers of Navan, Inc. common stock related to its IPO on October 31, 2025, where nearly 37 million shares were issued at $25.00 per share [1][2]. - The lawsuit claims that the offering documents were materially false or misleading, particularly regarding a 39% increase in sales and marketing expenses shortly after the IPO [3][4]. - Following the earnings report on December 15, 2025, which revealed increased expenses to nearly $95 million, Navan's stock price fell nearly 12% [4]. Group 2: Stock Performance - By the time the lawsuit commenced, Navan's stock price had dropped to as low as $9.20 per share, representing a nearly 63% decline from the IPO price of $25.00 [5]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Navan common stock during the IPO to seek appointment as lead plaintiff in the class action lawsuit [6]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [6]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [7]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history [7].

Core Viewpoint - A securities fraud lawsuit has been filed against Navan, Inc. and certain executives, alleging inadequate disclosure in the company's IPO materials regarding increased sales and marketing spending and slowing revenue trends [2]. Group 1: Lawsuit Details - The lawsuit claims that Navan's IPO offering materials, dated October 31, 2025, failed to disclose significant increases in sales and marketing expenses while the company was experiencing slowing revenue trends necessary to maintain reported growth metrics [2]. - Navan sold approximately 36.9 million shares at $25 per share during the IPO [2]. - Following the disclosure of increased sales and marketing expenses and the departure of the Chief Financial Officer on December 15, 2025, Navan's stock price fell to $12.90 per share the next trading day [2]. Group 2: Eligibility and Actions - Investors who purchased Navan common stock and experienced a decline in share value may be eligible to participate in the lawsuit, regardless of whether they sold their shares [3]. - The deadline to seek appointment as lead plaintiff is April 24, 2026, and a class has not yet been certified [4]. Group 3: Whistleblower Information - Individuals with non-public information about Navan are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [5]. Group 4: Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Corcept Therapeutics Incorporated during the specified Class Period, indicating potential legal issues surrounding the company's stock performance and disclosures [1]. Group 1: Class Action Details - The class action lawsuit is on behalf of investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must be appointed by April 21, 2026, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. Group 3: Case Specifics - The lawsuit claims that Corcept misrepresented the strength of clinical trials for relacorilant, suggesting it was a strong candidate for FDA approval, while the FDA had raised concerns about the clinical evidence [5]. - The defendants allegedly assured investors that there were no impediments to the New Drug Application (NDA) approval, which was later contradicted by the FDA's concerns [5]. - When the true situation regarding the NDA was revealed, investors reportedly suffered damages [5].

Core Viewpoint - A class action lawsuit has been filed against Ostin Technology Group Co., Ltd. for alleged securities fraud during the class period from May 11, 2025, to June 26, 2025, with significant losses reported by investors [2][5]. Allegation Details - The lawsuit alleges that on September 12, 2025, a criminal indictment was unsealed against Ostin's co-CEO Lai Kui Sen and financial advisor Yan Zhao, charging them with conspiracy to commit securities fraud and wire fraud, resulting in over $110 million in illicit proceeds [5]. - The complaint claims that starting in April 2025, Lai Kui Sen and co-conspirators executed fraudulent securities offerings, allowing them to acquire Ostin shares at minimal or no cost, while simultaneously inflating the stock price through deceptive promotional campaigns [5]. - Ostin's market capitalization reportedly increased from approximately $22 million to over $1 billion during the class period, with the stock price peaking at $9.40 on June 26, 2025, before a significant selloff led to a loss of over $950 million in market capitalization in one day [5]. Next Steps - Investors who purchased Ostin shares and suffered losses are encouraged to contact Bragar Eagel & Squire, P.C. for more information regarding their rights and potential claims [4].

Core Viewpoint - The Navan class action lawsuit alleges that Navan, Inc. and its executives misled investors regarding the company's financial health and future expenses during its IPO, leading to significant stock price declines after the IPO [1][3][4]. Company Overview - Navan, Inc. operates an AI-powered software platform aimed at simplifying travel and expense management for users, customers, and suppliers [2]. IPO Details - Navan conducted its IPO on October 31, 2025, issuing nearly 37 million shares at an offering price of $25.00 per share [2]. Allegations of Misleading Information - The lawsuit claims that the IPO offering documents were materially false or misleading, particularly regarding a 39% increase in sales and marketing expenses shortly after the IPO, which was necessary to sustain revenue growth [3]. Financial Impact - On December 15, 2025, Navan reported a significant increase in sales and marketing expenses to nearly $95 million, up from $68.5 million in the previous quarter, which contributed to a nearly 12% drop in stock price following the announcement [4]. - By the time the lawsuit commenced, Navan's stock price had fallen to as low as $9.20 per share, representing a decline of nearly 63% from the IPO price [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Navan common stock during the IPO to seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone, marking its fourth 1 ranking in the past five years [7].

Core Viewpoint - A class action lawsuit has been filed against Zynex, Inc. for alleged violations of federal securities laws, impacting investors who purchased Zynex securities between February 25, 2021, and December 15, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who acquired Zynex securities during the specified class period [2]. - The complaint alleges that Zynex's management made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations [3]. - Specific allegations include the shipment of excess products, which inflated revenue, and a fraudulent overbilling scheme that drew scrutiny from insurers [7]. Group 2: Allegations Against Management - The complaint states that Zynex's management prioritized aggressive sales strategies over compliance with industry regulations [7]. - It is alleged that the company's order growth was a result of illegal overbilling practices, leading to potential penalties and removal from insurer networks [7]. - The lawsuit claims that positive statements made by the defendants regarding the company's prospects were materially misleading [7]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis, meaning they will only collect fees if the case is successful [4]. - The firm has a history of recovering significant amounts for investors in securities fraud cases [5]. - Investors are encouraged to join the lawsuit and can contact the firm for more information [3][8].